ProCE Banner Activity

How New Data From IDWeek 2019 Estimate the Impact of PrEP Across Major US Cities

Conference Coverage
Clinical Thought
Earlier this year, the US government released a plan, with PrEP among its foundational pillars, to substantially reduce new HIV infections. Here’s my take on how data from IDWeek 2019 appraise progress toward this goal.

Released: December 06, 2019

Share

Faculty

David A. Wohl

David A. Wohl, MD

Associate Professor of Medicine
School of Medicine
Site Leader, AIDS Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Director, North Carolina AIDS Training and Education Center
Chapel Hill, North Carolina
Co-Director for HIV Services
North Carolina Department of Correction
Raleigh, North Carolina

Provided by

Provided by the USF Health
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

David A. Wohl, MD

Associate Professor of Medicine
School of Medicine
Site Leader, AIDS Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Director, North Carolina AIDS Training and Education Center
Chapel Hill, North Carolina
Co-Director for HIV Services
North Carolina Department of Correction
Raleigh, North Carolina

David A. Wohl, MD, has disclosed that he has served on advisory boards for and received funds for research support from Gilead Sciences, Merck, and ViiV Healthcare.